Skip to content
AnalystLens

Illumina 8-K Report, Corporate Update (Nov 12, 2025)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed November 12, 2025
Period End
November 10, 2025
Security
ILMN
In the record · 2016–202610-K1110-Q338-K167

ILMN filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 167 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Nov ’17Nov ’17
  2. Material agreement8-K · Sep ’20Sep ’20
  3. Leadership change8-K · Sep ’22Sep ’22
  4. Material agreement8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed November 12, 2025. Cited figures are marked; the original filing is the authoritative source.

On November 10, 2025, Illumina, Inc. entered into an Underwriting Agreement with Goldman Sachs & Co. LLC and BofA Securities, Inc., as representatives of the several underwriters, for the issuance and sale of $500,000,000a aggregate principal amount of its 4.750% notes due 2030 (the "Notes").

The offering is expected to close on November 25, 2025, subject to customary closing conditions. Illumina expects to use the net proceeds for general corporate purposes, which may include repaying its 5.800%b notes due December 12, 2025 and completing the proposed acquisition of SomaLogic, Inc., along with paying related fees and expenses. The Notes are being issued under a Registration Statement on Form S-3 (Registration No. 333-281921) filed with the SEC on September 4, 2024, and the Underwriting Agreement is filed as Exhibit 1.1 to this report for purposes of that registration statement.

For investors, the filing's key information is the size and timing of the debt offering and its stated uses, particularly the link to the pending SomaLogic acquisition and the maturing December 2025 notes. The filing does not state the Notes' pricing terms beyond the coupon, nor does it describe the acquisition's terms.

02—Key points

Key Highlights

  1. Illumina agreed on November 10, 2025 to sell $500,000,000 aggregate principal amount of 4.750% notes due 2030.
  2. Goldman Sachs & Co. LLC and BofA Securities, Inc. are the representatives of the underwriters.
  3. The offering is expected to close on November 25, 2025, subject to customary closing conditions.
  4. Net proceeds are expected for general corporate purposes, which may include repaying the 5.800% notes due December 12, 2025.
  5. Proceeds may also fund the proposed acquisition of SomaLogic, Inc. and related fees and expenses.
  6. The Notes are issued under a Form S-3 registration statement (No. 333-281921) filed September 4, 2024.
  7. The Underwriting Agreement is filed as Exhibit 1.1 to the 8-K.

03—Questions

Frequently Asked Questions

  1. How much debt is Illumina issuing and on what terms?

    Illumina is issuing $500,000,000 aggregate principal amount of 4.750% notes due 2030 under an Underwriting Agreement dated November 10, 2025. The filing does not state further pricing terms.

  2. When is the offering expected to close?

    The offering is expected to close on November 25, 2025, subject to customary closing conditions.

  3. What will Illumina use the proceeds for?

    The company expects to use the net proceeds for general corporate purposes, which may include repaying its 5.800% notes due December 12, 2025, and completing the proposed acquisition of SomaLogic, Inc., along with related fees and expenses.

  4. Under what registration statement are the Notes being sold?

    The Notes are being issued and sold under a Registration Statement on Form S-3 (Registration No. 333-281921), which Illumina filed with the SEC on September 4, 2024.

04—Continue

← View all 8-K filings